ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
ClaireMD
|
721 |
181K |
15 |
03/07/24 |
03/07/24 |
ASX - By Stock
|
721
|
181K
|
15
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
ClaireMD
|
721 |
181K |
15 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
721
|
181K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust reappoints MD and resets its sights on MND battle
|
|
ClaireMD
|
15 |
4.7K |
9 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
15
|
4.7K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust reappoints MD and resets its sights on MND battle
|
|
ClaireMD
|
15 |
4.7K |
9 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
15
|
4.7K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
ClaireMD
|
85 |
21K |
26 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
21K
|
26
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
ClaireMD
|
42 |
9.6K |
12 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
42
|
9.6K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
ClaireMD
|
86 |
21K |
21 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
86
|
21K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
ClaireMD
|
86 |
21K |
17 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
86
|
21K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
ClaireMD
|
86 |
21K |
25 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
86
|
21K
|
25
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
ClaireMD
|
1.4K |
366K |
27 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
1.4K
|
366K
|
27
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
ClaireMD
|
250 |
64K |
29 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
250
|
64K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
ClaireMD
|
250 |
64K |
4 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
250
|
64K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
ClaireMD
|
239 |
65K |
29 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
239
|
65K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
ClaireMD
|
239 |
65K |
28 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
239
|
65K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
ClaireMD
|
239 |
65K |
13 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
239
|
65K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
ClaireMD
|
239 |
65K |
23 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
239
|
65K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
ClaireMD
|
239 |
65K |
24 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
239
|
65K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
ClaireMD
|
104 |
20K |
6 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
104
|
20K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
ClaireMD
|
104 |
20K |
20 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
104
|
20K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
ClaireMD
|
239 |
65K |
26 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
239
|
65K
|
26
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
ClaireMD
|
239 |
65K |
35 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
239
|
65K
|
35
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
ClaireMD
|
261 |
73K |
29 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
261
|
73K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust makes Head of Manufacturing appointment
|
|
ClaireMD
|
37 |
9.6K |
4 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
37
|
9.6K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust makes Head of Manufacturing appointment
|
|
ClaireMD
|
37 |
9.6K |
16 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
37
|
9.6K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
ClaireMD
|
1.4K |
366K |
12 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
1.4K
|
366K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
ClaireMD
|
1.4K |
366K |
4 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
1.4K
|
366K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
ClaireMD
|
100 |
28K |
27 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
100
|
28K
|
27
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Presentation - Phase 1 Top-Line Results
|
|
ClaireMD
|
34 |
11K |
27 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
34
|
11K
|
27
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
ClaireMD
|
1.4K |
366K |
21 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
1.4K
|
366K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
ClaireMD
|
355 |
70K |
4 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
355
|
70K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
ClaireMD
|
355 |
70K |
7 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
355
|
70K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Oncology Data Supports Progression to Registration
|
|
ClaireMD
|
91 |
19K |
15 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
91
|
19K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Oncology Data Supports Progression to Registration
|
|
ClaireMD
|
91 |
19K |
10 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
91
|
19K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
ClaireMD
|
106 |
22K |
13 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
106
|
22K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
ClaireMD
|
380 |
85K |
11 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
380
|
85K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
ClaireMD
|
380 |
85K |
15 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
380
|
85K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Chief Executive Officer Appointment
|
|
ClaireMD
|
95 |
23K |
15 |
28/08/23 |
28/08/23 |
ASX - By Stock
|
95
|
23K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
ClaireMD
|
380 |
85K |
6 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
380
|
85K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
ClaireMD
|
380 |
85K |
9 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
380
|
85K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
ClaireMD
|
380 |
85K |
19 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
380
|
85K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
ClaireMD
|
218 |
51K |
6 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
218
|
51K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
ClaireMD
|
218 |
51K |
4 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
51K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
ClaireMD
|
218 |
51K |
10 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
51K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Successfully Completes 3rd Patient Cohort
|
|
ClaireMD
|
48 |
11K |
8 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
48
|
11K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
ClaireMD
|
396 |
85K |
11 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
396
|
85K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
ClaireMD
|
396 |
85K |
12 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
396
|
85K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Catalysts Before October to Enact The Options
|
|
ClaireMD
|
89 |
22K |
10 |
25/06/23 |
25/06/23 |
ASX - By Stock
|
89
|
22K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Trial Update
|
|
ClaireMD
|
205 |
44K |
10 |
21/06/23 |
21/06/23 |
ASX - By Stock
|
205
|
44K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Trial Update
|
|
ClaireMD
|
205 |
44K |
9 |
07/06/23 |
07/06/23 |
ASX - By Stock
|
205
|
44K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust MND Trial Interim Analysis PK Outcomes
|
|
ClaireMD
|
105 |
27K |
11 |
07/06/23 |
07/06/23 |
ASX - By Stock
|
105
|
27K
|
11
|
|